From: Current progress of fluoroquinolones-increased risk of aortic aneurysm and dissection
Duration of FQ use | No. of participants | OR (95% CI) | outcome | Reference | Study design |
---|---|---|---|---|---|
≤ 60 | 1477 case patients and 147,700 matched control cases | RR = 2.43, 95% CI 1.83–3.22 | AA or AD | 1 | A nested case–control analysis |
3–14 | 1213 hospitalized AA/AD patients | OR = 2.41; 95% CI 1.13–3.71 | 4 | A case-crossover design | |
≤ 60 | 360,088 | HR = 1.66; 95% CI 1.12–2.46 | AA or AD | 9 | Nationwide historical cohort study |
1,744,360 | Adjusted HR = 2.24, 95% CI 2.02–2.49 | AA | 40 | Population-based longitudinal cohort study | |
RR = 2.14; 95% CI 1.93–2.36 | AA or AD | 33 | A systematic review and meta-analysis | ||
19,207,552 | OR = 2.20; 95% CI 1.92–2.52 | AA or AD | 12 | Cohort and case–control studies | |
> 14 | OR = 2.83, 95% CI 1.06–7.57 | AAD | 42 | A prospective population-based study | |
14–60 | 1213 hospitalized AA/AD patients | OR = 2.83; 95% CI 1.13–3.71 | AA or AD | 4 | A case-crossover design |
61–120 | 360,088 | HR = 0.67; 95% CI 0.40–1.11 | None | 9 | Nationwide historical cohort study |
90 | 27,827,254 | HR = 1.31; 95% CI 1.25–1.37 | AAA | 41 | Cohort study |
27,827,254 | HR = 1.60; 95% CI 1.33–1.91 | Iliac artery aneurysm | 41 | Cohort study | |
27,827,254 | HR = 1.58; 95% CI 1.39–1.79 | Other AAA | 41 | Cohort study |